Pherecydes Pharma SA- Pipeline Review 2015- Ken Research


Global Markets Direct’s, Pherecydes Pharma SA- Pipeline Review-2015, provides an overview of the Pherecydes Pharma SA’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pherecydes Pharma SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class s.


The report provides brief overview of Pherecydes Pharma SA including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Pherecydes Pharma SA’s human therapeutic division and enlists all their major and minor projects

The report features description and descriptive mechanism of action for key pipeline s along with the developmental history and major milestones

Special feature on out-licensed and partnered portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest news and deals relating to the Pherecydes Pharma SA’s pipeline s

Evaluate Pherecydes Pharma SA’s strategic position with total access to detailed information on its pipeline

Assess the growth potential of Pherecydes Pharma SA in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Pherecydes Pharma SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Pherecydes Pharma SA and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pherecydes Pharma SA

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Pherecydes Pharma SA and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Key Topics covered in the report:-

Pherecydes Pharma Review

Pherecydes Pharma Market Research Report

Pherecydes Pharma Market Major Players

Pherecydes Pharma Market Size

Pherecydes Pharma Market share

Pherecydes Pharma Market trends

Pherecydes Pharma Market growth

Pherecydes Pharma Market Revenue

To know more about the publication, click on the link below:–pipeline/8714-91.html

Related Reports–2016/63876-91.html–pipeline/49970-91.html

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications



Comments are closed.